Swiss medical weekly最新文献

{"title":"Recommendations for perioperative pain medicine focusing on structures, processes, and organisation.","authors":"Benno Rehberg-Klug, Tobias Schneider, Ulrike Stamer","doi":"10.57187/4797","DOIUrl":"10.57187/4797","url":null,"abstract":"<p><p>This article presents a comprehensive overview of perioperative pain medicine based on recently published recommendations by the Swiss Society of Anaesthesiology and Perioperative Medicine (SSAPM). As it has long been known that improvements in postoperative pain management depend more on organisational structures than on new drugs or techniques, these recommendations focus on the structures and processes of perioperative pain management. The introduction of Acute Pain Services (APS) by anaesthesiology departments in the 1980s marked significant progress. However, APS coverage remains limited and inconsistent across institutions, often lacking sufficient resources. To address these gaps, the SSAPM convened a multiprofessional expert group to develop structural and procedural recommendations. Key structural recommendations emphasise the necessity of interdisciplinary and interprofessional collaboration, with jointly developed and signed protocols between surgical and pain services to clarify responsibilities and prevent care gaps. Hospitals are urged to maintain written, evidence-based standard procedures for multimodal pain management tailored to local conditions. The availability of qualified personnel for pain management is also a key recommendation. Process recommendations highlight the importance of multidisciplinary, multiprofessional approaches and seamless communication between personnel involved in perioperative care, patients, and external care providers. Preoperative patient education, the identification of individuals at risk for complex pain trajectories or chronic postsurgical pain (CPSP), and structured follow-up are essential components. The continuum of care from inpatient to outpatient settings is another key element. Overall, these recommendations aim to standardise and define perioperative pain management as a core element of modern perioperative medicine.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4797"},"PeriodicalIF":1.6,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Aare You Safe?\" River-related presentations and clinical outcomes at a Swiss tertiary emergency department: a retrospective cross-sectional study.","authors":"Julius Husarek, Thomas Maurer, Tany Zuerrer, Karsten Klingberg, Aristomenis Exadaktylos, Sabrina Jegerlehner, Martin Mueller","doi":"10.57187/4839","DOIUrl":"10.57187/4839","url":null,"abstract":"<p><p>BACKGROUND: Urban swimming, especially in the Aare River, is popular in Switzerland but carries risks, particularly for those unfamiliar with its currents and hazards. This study describes the epidemiology of river-related emergency department (ED) visits, focusing on injury patterns, patient demographics and presentation characteristics.</p><p><strong>Methods: </strong>A retrospective cross-sectional study at the University Hospital of Bern was conducted, analysing river-related ED visits from 2012 to 2024. Data on demographics, injury types, triage levels and outcomes were extracted from electronic medical records.</p><p><strong>Results: </strong>A total of 263 river-related ED visits were identified among a total of 541,561 ED visits over the study period (proportional incidence: 0.49 per 1000 ED consultations, 95% CI: 0.43-0.55). Most patients were male (62.7%), aged ≤35 years (65.4%) and Swiss nationals (65.4%). The most frequent injuries were trauma (63.1%), mainly affecting the lower extremities (30.8%) and head/face (16.3%), often due to collisions with submerged objects or bridge jumping. Drowning cases (12.2%) were less common, with seven fatalities (2.7%). Most incidents occurred in the summer between June and August (78.7%), with 37.3% on weekends. Suicide attempts (20.4% vs 3%) and boating-related incidents (11.2% vs 6.7%) were more common in females and jumping-related incidents more frequent in males (22.4% vs 11.2%), p <0.001. Hypothermia was significantly more often found in non-Swiss nationality ED visits (p = 0.002) and those of people aged >35 years (p <0.001). Compared to younger patients, those aged >35 years were significantly more likely to be triaged as life-threatening (22% vs 7.6%; p <0.001), report intentions other than swimming (notably more suicide attempts and accidents; p <0.001), and had higher rates of admission to an ICU or of transfer to a psychiatric clinic (p <0.001).</p><p><strong>Conclusion: </strong>River-related ED visits are a recurring seasonal concern, primarily affecting young males. People with non-Swiss nationality and those engaging in high-risk activities are at higher risk. Adopting a multilingual approach could be a key objective of safety campaigns to more effectively reduce risks for non-Swiss swimmers and promote safer swimming practices in urban waters. Prevention efforts should continue to focus on public education, enhanced safety signage and improved emergency preparedness.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4839"},"PeriodicalIF":1.6,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilirubin interference in creatinine assays: cross-sectional analysis of the impact on the MELD score and CKD staging using Jaffe vs enzymatic methods.","authors":"Kathrin Frey, Joanna Gawinecka, Arnold Von Eckardstein, Lanja Saleh","doi":"10.57187/4707","DOIUrl":"10.57187/4707","url":null,"abstract":"<p><strong>Background: </strong>Reliable and accurate measurement of creatinine is essential for the estimation of kidney function (eGFR) and for survival prediction with the model of the end-stage liver disease (MELD) score. Bilirubin interference is considered an important interference of Jaffe creatinine assays; the enzymatic assay is also affected but less so. This study aimed to evaluate the comparability of the Jaffe and enzymatic creatinine methods and the impact of their discrepancy on clinical decision-making, particularly in the context of bilirubin interference.</p><p><strong>Methods: </strong>We compared creatinine measurements from the Roche Jaffe Gen.2 (CREJ2) and Roche Creatinine Plus ver.2 (CREP2) assays using routine heparin plasma samples (n = 15,618). To estimate the clinical impact of bilirubin interference on these two assays, we evaluated our results in the context of eGFR-based staging of severity of kidney disease and the MELD score.</p><p><strong>Results: </strong>The Roche Jaffe and enzymatic methods agree well for non-icteric samples with a mean relative bias of 3.97% but not in icteric samples. In samples with 5-20 mg/dl and 20-53 mg/dl bilirubin, the biases amounted to 10.9% and 43.4%, respectively.</p><p><strong>Conclusions: </strong>The Jaffe method's susceptibility to bilirubin interference, in comparison to the enzymatic assay, can result in higher MELD scores and can lead to an underestimation of kidney function.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4707"},"PeriodicalIF":1.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis.","authors":"Mirjam Kolev, Salomé Wolf, Elizabeth Petràš, Véronique Erard, Beat Helbling, Beat Müllhaupt, David Semela, Felix Stickel, Nasser Semmo","doi":"10.57187/4736","DOIUrl":"10.57187/4736","url":null,"abstract":"<p><p>BACKGROUND AND AIMS: Bulevirtide 2 mg/day was approved in Switzerland in February 2025 for the treatment of chronic hepatitis D virus (HDV) infection. We present real-world data on efficacy and safety in patients treated under an early access programme.</p><p><strong>Methods: </strong>This retrospective, multicentre Swiss cohort study included patients with compensated HDV-associated cirrhosis in whom bulevirtide therapy (2 mg/day) was initiated between January 2020 and August 2024 under a compassionate use programme. Virological response was defined as a HDV RNA level that was undetectable or declined ≥2 log10 IU/ml from baseline. Biochemical response was defined as normalisation of ALT. Combined response was defined as achieving both virological and biochemical response. Liver-related events and adverse events were assessed.</p><p><strong>Results: </strong>Fourteen patients with compensated HDV-related cirrhosis received bulevirtide for a median duration of 1.85 years (1.1-2.1). Median age was 51.3 years (43.9-58.5), and 71.4% were men. Baseline ALT was 81 U/l (55.8-88.8), platelet count 102.5 × 109/l (67.3-141.3) and liver stiffness 15.3 kPa (11.8-22.1). Baseline HDV RNA was 4.82 log10 IU/ml (4.52-6.23). Biochemical, virological and combined responses were observed in 50%, 64.3% and 35.7% at 6 months; 66.7%, 75% and 58.3% at 12 months; and 62.5% for all three response types at 24 months. Two patients (14.3%) developed de novo hepatocellular carcinoma, and one (7.14%) patient underwent liver transplantation. No serious adverse events were reported. Mild transient pruritus occurred in two (14.3%) patients.</p><p><strong>Conclusions: </strong>In this real-world cohort of patients with compensated HDV cirrhosis, bulevirtide demonstrated favourable efficacy and safety. These findings support the integration of bulevirtide into routine care for patients with HDV and compensated cirrhosis in Switzerland following its reimbursement status as of 2025. Longer-term follow-up is warranted to assess the impact on liver-related outcomes.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4736"},"PeriodicalIF":1.6,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A qualitative assessment of the use of artificial intelligence in public sector health organisations in Ontario, Canada.","authors":"Steven Habbous, Jeremy Herring, Tina Badiani, Adalsteinn Brown, Michael Hillmer, Laura C Rosella","doi":"10.57187/4942","DOIUrl":"10.57187/4942","url":null,"abstract":"<p><strong>Background: </strong>Advancements in artificial intelligence (AI) and machine learning (ML) capabilities and increased access to methods have enabled population-level analysis for research and health system monitoring. However, governments and public authorities may not be aware of the full range of applications, opportunities, and barriers and challenges. The purpose of the present study was to understand the barriers and facilitators of AI/ML and whether (and how) AI/ML was being used (or could be used) in public sector health organisations in a publicly funded health system.</p><p><strong>Methods: </strong>Thirteen key informant interviews at three public sector health organisations were conducted. Common themes were identified. An in-person workshop was held in Toronto on 15 May 2024. We identified barriers and enablers and make recommendations for advancing AI/ML in the broader public sector.</p><p><strong>Results: </strong>A total of six barriers were identified by participants: 1) knowledge, education and expertise; 2) privacy, ethics and security; 3) technology and infrastructure; 4) financial barriers; 5) competing priorities; and 6) fear of being replaced. Key enablers include 1) partnerships; 2) buy-in and support from senior leadership; 3) management and operational supports; and 4) actionable use cases. One prominent use case objective was to enhance healthcare system efficiency, including automating routine or unskilled operations to allow healthcare professionals to focus on higher-value tasks.</p><p><strong>Conclusion: </strong>Demonstrating success from focused small-scale AI applications, partnering with academia, and engaging senior leadership may build confidence and capability, but it is important to share knowledge, experiences, and measure success for the perspectives of different partners.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4942"},"PeriodicalIF":1.6,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends over time and risk factors in inappropriate prescribing in older adults with multimorbidity and polypharmacy: a longitudinal secondary analysis of the OPERAM trial.","authors":"Jonathan Huschka, Katharina Tabea Jungo, Valerie Aponte Ribero, Lara Brockhus, Denis O'Mahony, Mary Randles, Sophie Marien, Clara Drenth, Anne Spinewine, Wilma Knol, Drahomir Aujesky, Nicolas Rodondi, Carole E Aubert","doi":"10.57187/4892","DOIUrl":"10.57187/4892","url":null,"abstract":"&lt;p&gt;&lt;p&gt;BACKGROUND AND AIM OF THE STUDY: Polypharmacy is common among older adults and associated with potentially inappropriate medications and potential prescribing omissions, which together constitute potentially inappropriate prescriptions, contributing to adverse outcomes and increased healthcare costs. Longitudinal data on potentially inappropriate prescriptions and differences across living environments are limited. Our aim was to analyse patterns and determinants of potentially inappropriate prescriptions in multimorbid, older adults across different living environments and their trends over 12 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We used data from the control group (n = 1045) of the multi-country OPERAM trial (December 2015 - October 2018), a cluster-randomised controlled trial including older adults aged ≥70 years with ≥3 chronic conditions and ≥5 medications, which tested a software intervention to improve prescribing in these patients. The control group received pharmaceutical care in accordance with usual care. STOPP/START criteria were applied to detect potentially inappropriate prescriptions at hospital admission, discharge, and at 2-, 6- and 12-month follow-up. The outcomes were a priori defined as the prevalence of potentially inappropriate prescriptions at hospital admission, differences in potentially inappropriate prescriptions between living settings (nursing home versus community-dwelling) and number of medications (polypharmacy [5-9 medications] versus hyperpolypharmacy [≥10 medications]), changes in potentially inappropriate prescriptions over the 12-month follow-up and factors associated with potentially inappropriate prescriptions. Analyses included descriptive statistics and multivariable regression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;At admission, 664 (63.5%) patients had ≥1 potentially inappropriate medication and 754 (72.1%) had ≥1 potential prescribing omission. Potentially inappropriate prescriptions at admission were most strongly associated with hyperpolypharmacy (potentially inappropriate medication: incidence rate ratio [IRR] 1.54, 95% CI 1.35-1.76) and cognitive impairment (potentially inappropriate medication: IRR 1.44, 95% CI 1.16-1.79), and were also significantly associated with female sex, number of comorbidities, fall history, nursing home residency and older age. Although overall prevalence remained stable over 12 months, substantial individual-level changes occurred, with many patients experiencing increases or decreases in the number of potentially inappropriate medications or potential prescribing omissions, alongside notable shifts in specific potentially inappropriate medications/potential prescribing omissions. An increasing number of potentially inappropriate prescriptions over time was mostly associated with hyperpolypharmacy (potential prescribing omission: OR 1.71, 95% CI 1.20-2.42 at 12 months) and nursing home residency (potentially inappropriate medication: OR 1.94, 95% CI 1.12-3.36 at 12 mon","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4892"},"PeriodicalIF":1.6,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation.","authors":"Emma Shittu, Barbara A Pahud, David Radley, Alejandra Gurtman, Iona Munjal","doi":"10.57187/4711","DOIUrl":"10.57187/4711","url":null,"abstract":"<p><strong>Aims of the study: </strong>Marketing authorisation of the bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) for maternal vaccination was predominantly based on safety and efficacy findings from the pivotal global phase 3 Maternal Immunization Study for Safety and Efficacy (MATISSE) trial that included >7000 pregnant women and their infants. The aim of this post hoc analysis was to evaluate clinical efficacy and safety endpoints within the subgroup of participants from the MATISSE trial who received RSVpreF or placebo at 32-36 weeks of gestation, which is the indicated gestational age (GA) window for maternal RSVpreF vaccination in Switzerland.</p><p><strong>Methods: </strong>Healthy pregnant women ≤49 years of age with uncomplicated, singleton pregnancies were randomised 1:1 to receive a single dose of RSVpreF 120 μg or placebo. Primary efficacy endpoints were vaccine efficacy against severe medically attended RSV-associated lower respiratory tract illness and medically attended RSV-associated lower respiratory tract illness in infants occurring within 90 and 180 days after birth. This is a descriptive post hoc analysis of efficacy and safety endpoints from MATISSE among the subgroup of newborns whose mothers received RSVpreF or placebo at 32-36 weeks of gestation.</p><p><strong>Results: </strong>Of 7392 maternal participants included in the primary MATISSE analysis, 3285 (RSVpreF: 1653; placebo: 1632) received vaccination at a GA of 32-36 weeks and were included in this analysis. Efficacy was evaluated in a total of 1628 and 1604 infants who were born to mothers receiving RSVpreF or placebo, respectively. RSVpreF vaccine efficacy percentages against severe medically attended RSV-associated lower respiratory tract illness were 91.1% (95% CI: 38.8-99.8%) and 76.5% (95% CI: 41.3-92.1%) within 90 and 180 days of birth, respectively. RSVpreF vaccine efficacy percentages against medically attended RSV-associated lower respiratory tract illness were 34.7% (95% CI: -34.6-69.3%) and 57.3% (95% CI: 29.8-74.7%) within 90 and 180 days of birth, respectively. Adverse event profiles for maternal and infant participants were generally similar between RSVpreF and placebo groups in this post hoc analysis; safety results were consistent with those of the primary and final analyses.</p><p><strong>Conclusions: </strong>Maternal vaccination with RSVpreF in pregnant women at 32-36 weeks of gestation is safe and efficacious against RSV-associated lower respiratory tract illness in infants to 6 months of age, aligning with the outcomes of the primary analysis.</p><p><strong>Clinicaltrials: </strong>gov: NCT04424316.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4711"},"PeriodicalIF":1.6,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swiss caesarean section rates according to Robson's Ten-Group Classification System: an observational study.","authors":"Stephen Adjahou, Gian-Paolo Klinke, Alexandre Vallée, Benedetta Guani, Nordine Ben Ali, Jean-Marc Ayoubi, Anis Feki, Arrigo Fruscalzo","doi":"10.57187/4231","DOIUrl":"10.57187/4231","url":null,"abstract":"<p><strong>Study aims: </strong>Robson's Ten-Group Classification System (TGCS) was proposed to describe caesarean section rates by ten patient-centred risk-specific groups. The aim of the study was to describe Swiss caesarean section rates according to this classification, further stratifying it according to region and type of structure where delivery took place.  We also aimed to compare our results to the standard caesarean section rates, recommended by the World Health Organization (WHO).</p><p><strong>Methods: </strong>An observational study including all women delivering in health facilities in Switzerland in the period 2014-2021. A total of 695,733 deliveries were included. Core variables used for classification were semi-automatically generated using routine data provided by the Swiss Federal Statistics Office. Caesarean section rates were reported according to the TGCS. Data were also stratified according to each of the 26 Swiss cantons, as well as to the typology of hospital where delivery took place.</p><p><strong>Results: </strong>The major relative contributors to the overall caesarean section rate were Group 2 (nulliparous, above 37 weeks, with induction) and Group 5 (women with previous caesarean section, above 37 weeks with a singleton pregnancy), respectively accounting for 20.7% and 30.1% of all caesarean sections. We also showed that the Swiss population was similar to the population considered in the WHO recommendation. Nonetheless, the caesarean section rate among our population exceeded that suggested by the WHO recommendations, being respectively of 44.4% vs 39.9% and 86.0% vs 74.4% for Groups 2 and 5. Large variations were detected in the caesarean section rate when looking at the different cantons, ranging from 29.8% to 59.6% for Group 2 and between 58.0% and 100.0% for Group 5.</p><p><strong>Conclusion: </strong>Routine data collection allowed us to describe caesarean section rates throughout Switzerland according to the TGCS. The Swiss caesarean section rate was higher than the caesarean section rate recommended by the WHO, even though the population characteristics were comparable. Substantial differences were found when stratifying caesarean section rates according to the canton, as well as to the type of structure where delivery took place.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"4231"},"PeriodicalIF":1.6,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pigmented purpuric dermatosis in two patients with common variable immunodeficiency.","authors":"Vincenzo Papa, Alessandra Bennici, Luisa Ricciardi, Paolina Quattrocchi, Sebastiano Gangemi, Paola Lucia Minciullo","doi":"10.57187/3993","DOIUrl":"10.57187/3993","url":null,"abstract":"<p><p>Pigmented purpuric dermatosis is a benign type of chronic angiodermatitis prevalent in the general population, presenting with a relapsing-remitting course, with predominantly idiopathic aetiology and both humoral and cell-mediated immune pathogenesis. We report to our knowledge the first two cases of clinical association between such dermal capillaritis and the most clinically heterogeneous form of primary immunodeficiency: common variable immunodeficiency. Furthermore, in the light of already suggested triggers and pathophysiological mechanisms correlating pigmented purpuric dermatosis with various forms of secondary immunodeficiency, we complete our case descriptions by the proposal of a new putative aetiopathogenic actor that would likely account for the occurrence of the clinical association described.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"3993"},"PeriodicalIF":1.6,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementum 295: Abstracts of the 48th IHF World Hospital Congress (Geneva, November 10-13, 2025).","authors":"International Hospital Federation","doi":"10.57187/5258","DOIUrl":"10.57187/5258","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}